| Literature DB >> 36058932 |
Jessica Kåhlin1,2, Emma Larsson3,4,5, Lars Engerström6,7,8, Johan Thermaenius1,2, Johan Mårtensson1,2, Anders Oldner1,2, Johan Petersson1,2.
Abstract
BACKGROUND: COVID-19 ARDS shares features with non-COVID ARDS but also demonstrates distinct physiological differences. Despite a lack of strong evidence, prone positioning has been advocated as a key therapy for COVID-19 ARDS. The effects of prone position in critically ill patients with COVID-19 are not fully understood, nor is the optimal time of initiation defined. In this nationwide cohort study, we aimed to investigate the association between early initiation of prone position and mortality in mechanically ventilated COVID-19 patients with low oxygenation on ICU admission.Entities:
Keywords: ARDS; COVID-19; Critical illness; Mortality; Outcome; Prone position; Ventilation
Mesh:
Year: 2022 PMID: 36058932 PMCID: PMC9441133 DOI: 10.1186/s13054-022-04122-w
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 19.334
Fig. 1Flow chart of included patients
Fig. 2Identification of patients with early mechanical ventilation and PaO2/FiO2 ≤ 20 kPa at ICU admission
Characteristics for patients with PaO2/FiO2 ≤ 20 kPa on invasive mechanical ventilation within 24 h from ICU admission
| All | Early prone = NO | Early prone = YES | |
|---|---|---|---|
| No. (%) | 1714 | 1144 (66.7) | 570 (33.3) |
| Women | 512 (29.9) | 346 (30.2) | 166 (29.2) |
| Age, median (IQR), y | 64 (55–71) | 64 (55–71) | 64 (54–71) |
| < 40 | 85 (5) | 61 (5.3) | 24 (4.2) |
| 40–49 | 175 (10.2) | 117 (10.2) | 58 (10.2) |
| 50–59 | 387 (22.6) | 254 (22.2) | 133 (23.3) |
| 60–69 | 549 (32) | 362 (31.6) | 187 (32.8) |
| 70–79 | 459 (26.8) | 309 (27) | 150 (26.3) |
| ≥ 80 | 59 (3.4) | 41 (3.6) | 18 (3.2) |
| March – April 2020 | 514 (30) | 426 (37.2) | 88 (15.4) |
| May – August 2020 | 228 (13.3) | 162 (14.2) | 66 (11.6) |
| September – December 2020 | 326 (19) | 203 (17.7) | 123 (21.6) |
| January – April 2021 | 646 (37.7) | 353 (30.9) | 293 (51.4) |
| Emergency department | 398 (23.2) | 242 (21.2) | 156 (27.4) |
| Hospital floor | 1316 (76.8) | 902 (78.8) | 414 (72.6) |
| No. with data | 1688 | 1124 | 564 |
| Median (IQR), d | 10 (7–13) | 10 (7–13) | 10 (8–14) |
| Tertiary | 576 (33.6) | 376 (32.9) | 200 (35.1) |
| County | 964 (56.2) | 636 (55.5) | 328 (57.5) |
| Local | 174 (10.2) | 132 (11.5) | 42 (7.4) |
| Median (IQR), d | 2 (0–4) | 2 (0–4) | 2 (0–5) |
| Pregnant, No | 16 | 14 | 2 |
| None | 493 (28.8) | 356 (31.1) | 137 (24.0) |
| One or more | 1221 (71.2) | 788 (68.9) | 433 (76.0) |
| Chronic hypertension | 825 (48.1) | 521 (45.5) | 304 (53.3) |
| Chronic cardiac disease | 239(13.9) | 162(14.2) | 77 (13.5) |
| COPD/Asthma | 275 (16.0) | 178(15.6) | 97(17) |
| Immune deficiency | 130 (7.6) | 77 (6.7) | 53 (9.3) |
| Chronic liver disease | 12 (0.7) | 7 (0.6) | 5 (0.9) |
| Chronic kidney disease | 97 (5.7) | 69 (6.0) | 28 (4.9) |
| Diabetes | 484 (28.2) | 321 (28.1) | 163 (28.6) |
| Neuromuscular disease | 18 (1.1) | 10 (0.9) | 8 (1.4) |
| Obesitya | 188 (11.0) | 111 (9.7) | 77 (13.5) |
| Malignancyb | 31 (1.8) | 21 (1.8) | 10 (1.8) |
IQR, interquartile range; y: years; d: days; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease
aObesity is defined as BMI > 40 kg/m2
bMalignancy is defined as neoplasia spread beyond regional lymph nodes
ICU-parameters for patients with PaO2/FiO2 ≤ 20 kPa on invasive mechanical ventilation within 24 h from ICU admission
| PaO2, kPa. Median (IQR) | 8.5 (7.4–9.8) | 8.6 (7.4–9.9) | 8.3 (7.3–9.4) |
| FiO2, %. Median (IQR) | 80 (70–100) | 80 (65–95) | 85 (70–100) |
| PaO2/FiO2 ratio. Median (IQR) | 11.0 (8.5–14.2) | 11.6 (8.8–14.8) | 9.9 (8.0–12.6) |
| > 13.3—≤ 26.6 | 525 (30.6) | 415 (36.3) | 110 (19.3) |
| ≤ 13.3 | 1189 (69.4) | 729 (63.7) | 460 (80.7) |
| Vasopressor on admission, No (%) | 107 (6.2) | 73 (6.4) | 34 (6.0) |
| No with data | 1647 | 1094 | 553 |
| Degrees Celsius | 37.8 (37.0–38.4) | 37.8 (37.0–38.5) | 37.8 (37.1–38.3) |
| Fevera, No (%) | 602 (36.6) | 423 (38.6) | 180 (32.5) |
| No. with data | 1669 | 1103 | 566 |
| Median (IQR) | 119 (95–135) | 116 (95–134) | 120 (100–139) |
| No. with data | 1681 | 1116 | 565 |
| Median (IQR) | 95 (82–110) | 95 (80–110) | 98 (84–112) |
| No. with data | 1638 | 1084 | 554 |
| Median (IQR) | 9.3 (6.8–12.9) | 9.0 (6.5–12.6) | 9.9 (7.3–13.1) |
| No. with data | 1699 | 1130 | 569 |
| Median (IQR) | 7.43 (7.35–7.47) | 7.43 (7.35–7.47) | 7.44 (7.36–7.48) |
| No. with data | 1636 | 1085 | 551 |
| Median (IQR) | 72 (58–95) | 71 (58–99) | 72 (58–91) |
| No. with data | 1596 | 1047 | 549 |
| Median (IQR) | 9 (6–12) | 9 (6–12) | 9 (6–12) |
| SAPS3 at admission, median (IQR) | 58 (53–65) | 58 (53–65) | 58 (53–66) |
| Predicted risk of death (SAPS3), median (IQR), % | 32 (22–48) | 32 (22–46) | 32 (22–48) |
| 30-day mortality | 500 (29.2) | 345 (30.2) | 155 (27.2) |
| 90-day mortality | 575 (33.5) | 398 (34.8) | 177 (31.1) |
IQR, interquartile range; y: years; d: days; ICU, intensive care unit; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; SAPS, simplified acute physiology score
aFever is defined as body temperature above 38 °C
ICU care provided for patients in study-population with low oxygenation and early mechanical ventilation
| Variable | No (%) | ||
|---|---|---|---|
| All | Early prone = NO | Early prone = YES | |
| Duration of invasive mechanical ventilation, median (IQR) h | 267 (143–450) | 265 (137–452) | 269 (165–444) |
| Renal replacement therapy, No./total (%) | 312/1638 (19.0) | 219/1082 (20.2) | 93/556 (16.7) |
| ECMO, No./total (%) | 23/982 (2.3) | 17/660 (2.6) | 6/322 (1.9) |
| Tracheostomy, No. (%) | 578 (33.7) | 389 (34.0) | 189 (33.2) |
| More than one ICU admissiona | 576 (33.6) | 408 (35.7) | 168 (29.5) |
| ICU length of stay, median (IQR), d | 14 (8–22) | 14 (8–22) | 14 (9–22) |
IQR, interquartile range; ECMO, extracorporeal membrane oxygenation; h, hours; ICU, intensive care unit; d, days
aMost often due to optimization of ICU resources
Fig. 3Time to death for the total study cohort and the study population a Time to death for the total study cohort (6350 patients) b Time to death for the study population (1714 patients)
Univariate and multivariable logistic regression analysis for 30-day mortality
| Univariate | Multivariable | |||
|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | |
| Prone | ||||
| Early = no | Reference | Reference | ||
| Early = yes | 0.86 (0.69—1.08) | 0.2035 | 0.92 (0.71—1.19) | 0.5206 |
| Sex | ||||
| Women | Reference | Reference | ||
| Men | 1.33 (1.05—1.68) | 0.0183 | 1.28 (0.99—1.67) | 0.0645 |
| Age, per year | 1.07 (1.06—1.09) | < 0.001 | 1.07 (1.06—1.09) | < 0.001 |
| Comorbidity | ||||
| Cardiac disease | 1.93 (1.46—2.56) | < 0.001 | 1.14 (0.83—1.57) | 0.4203 |
| COPD/Asthma | 1.08 (0.81—1.43) | 0.5844 | 1.15 (0.84—1.56) | 0.3846 |
| Diabetes | 1.22 (0.97—1.54) | 0.0807 | 1.12 (0.86—1.45) | 0.4021 |
| Obesitya | 0.63 (0.43—0.89) | 0.0122 | 1.15 (0.76—1.72) | 0.4979 |
| Hypertension | 1.33 (1.08—1.64) | 0.0071 | 0.86 (0.67—1.10) | 0.2276 |
| Immune deficiency | 1.52 (1.04—2.19) | 0.0271 | 1.60 (1.05—2.42) | 0.0279 |
| Chronic liver disease | 0.81 (0.18—2.72) | 0.7502 | 0.57 (0.11—2.33) | 0.4637 |
| Chronic kidney disease | 1.61 (1.05—2.44) | 0.0268 | 1.05 (0.65—1.66) | 0.8535 |
| Neuromuscular disease | 0.69 (0.20—1.94) | 0.5167 | 0.62 (0.17—1.92) | 0.4384 |
| Malignancyb | 3.02 (1.48—6.26) | 0.0025 | 2.12 (0.97—4.69) | 0.0585 |
| PaO2/FiO2 ratio, per 1 kPa increase | 0.97 (0.94—1) | 0.0370 | 0.98 (0.95 – 1.02) | 0.3362 |
| SAPS3c, per 1 unit increase | 1.05 (1.04—1.07) | < 0.001 | 1.05 (1.04—1.07) | < 0.001 |
| Admission months | ||||
| March – April 2020 | Reference | Reference | ||
| May – August 2020 | 0.57 (0.39—0.83) | 0.0037 | 0.45 (0.30—0.68 | < 0.001 |
| September – December 2020 | 1.19 (0.88—1.60) | 0.2489 | 0.80 (0.57—1.11) | 0.1848 |
| January – April 2021 | 0.91 (0.71—1.18) | 0.4793 | 0.62 (0.46—0.83) | 0.0014 |
OR, Odds Ratio; CI, Confidence Interval; COPD, chronic obstructive pulmonary disease; PaO2, arterial partial pressure of oxygen; FiO2, fraction of inspired oxygen; SAPS, simplified acute physiology score
aObesity defined as BMI > 40 kg/m2
bMalignancy is defined as neoplasia spread beyond regional lymph nodes
cRecalculated after excluding age, comorbidities and PaO2/FiO2 ratio
aROC 0.749 for full model